Paratek Expands Leadership Team

Paratek Pharmaceuticals Inc. has expanded its senior leadership team. Raj Padmanabhan has joined as vice president, information technology (IT), and Judith Steenbergen, has been named executive director, microbiology. Mr. Padmanabhan will be based in Paratek’s Boston headquarters and Dr. Steenbergen will be based in the company’s Philadelphia offices. Paratek is a biopharmaceutical company focused on the development and commercialization of therapies based upon tetracycline chemistry. Its lead compound, omadacycline, is in Phase 3 development.

“These two new hires are important to Paratek’s growth. Judith’s deep experience in clinical microbiology will be vital as we further define the potential role of omadacycline against multi-drug resistant organisms,” said Michael Bigham, chairman and chief executive officer, Paratek. “At the same time, Raj’s leadership will be critical toward ensuring we have the appropriate technological infrastructure to support our needs as we prepare for the launch and commercialization of omadacycline and continue to expand operational needs in both Boston and Philadelphia.”